European Commission To Allow Pre-MDD Non-CE Mark Devices Until 2001
This article was originally published in The Gray Sheet
Executive Summary
Recommendations concerning the use of non-CE marked devices after June 14 in member states have recently been upgraded to a "communication" by the European Commission, Smith & Nephew Director of European Regulatory Affairs Ian Cutler told attendees of a European device conference June 25 in Washington, D.C.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.